Interferon alfa-n3 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c).
- Mechanism
- Curator reviewed
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
- Primary indication
- For the intralesional treatment of refractory or recurring external condylomata acuminata.Curator reviewed
- First approval
- United States, 1989
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Interferon alfa-n3, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account